Log in to search using one of your social media accounts:

 

Time to Revise the FDA Black Box Warning for TCIs?Time to Revise the FDA Black Box Warning for TCIs?
Dr Graeme M. Lipper summarizes the results of a recent study that assessed the risk for malignancy in children who used intermittent pimecrolimus 1% cream to treat their atopic dermatitis. Medscape Dermatology (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 25, 2015 Category: Dermatology Tags: Dermatology Viewpoint Source Type: news

Pediatric Atopic Dermatitis: Pimecrolimus Safe, EffectivePediatric Atopic Dermatitis: Pimecrolimus Safe, Effective
Pimecrolimus is a safe and effective alternative to topical corticosteroids for infants and young children with mild to moderate atopic dermatitis. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 24, 2015 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Pimecrolimus cream safe, effective for atopic dermatitis in young children
Using pimecrolimus cream as a first-line treatment for atopic dermatitis in infants spares the need for topical corticosteroids as frequently and appears safe over the long term, according to a study published online March 23 in Pediatrics. “The efficacy results suggest that pimecrolimus has... (Source: Skin and Allergy News)
Source: Skin and Allergy News - March 23, 2015 Category: Dermatology Tags: CME-candidate FPN Journals FPN News FPN Allergy & Immunology FPN Child Adolescent Medicine FPN Dermatology SAN Journals Source Type: news

Pimecrolimus for Eczema May Have No Added Cancer Risk After AllPimecrolimus for Eczema May Have No Added Cancer Risk After All
Topical pimecrolimus as a treatment for eczema may have no significant cancer risk, contrary to a U.S Food and Drug Administration warning, according to new research published online February 18 in JAMA Dermatology. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 26, 2015 Category: Dermatology Tags: Dermatology News Source Type: news

Unlikely that topical pimecrolimus associated with increased risk of cancer
The topical medicine pimecrolimus to treat eczema (atopic dermatitis or AD) in children appears unlikely to be associated with increased of risk of cancer based on how it was used in group of children followed for 10 years, according to an article. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 18, 2015 Category: Science Source Type: news

Unlikely that topical pimecrolimus associated with increased risk of cancer
(The JAMA Network Journals) The topical medicine pimecrolimus to treat eczema (atopic dermatitis or AD) in children appears unlikely to be associated with increased of risk of cancer based on how it was used in group of children followed for 10 years, according to an article published online by JAMA Dermatology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 18, 2015 Category: Cancer & Oncology Source Type: news

ELIDEL (Pimecrolimus) Cream [Valeant Pharmaceuticals North America LLC]
Updated Date: Apr 3, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - April 3, 2014 Category: Drugs & Pharmacology Source Type: news